MODUS THERAPEUTICS HLDG
Modus Therapeutics Holding AB (publ), a biotechnology company, develops a treatment for sepsis and septic shock in Sweden. It develops Sevuparin, a lipopolysaccharide in Phase IIa trial to treat patients with sepsis, septic shock, anemia associated with chronic kidney disease, endotoxemia, severe malaria, and other diseases involving severe systemic inflammation. Modus Therapeutics Holding AB (pu… Read more
MODUS THERAPEUTICS HLDG (99Z) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, MODUS THERAPEUTICS HLDG (99Z) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
MODUS THERAPEUTICS HLDG - Net Assets Trend (None–None)
This chart illustrates how MODUS THERAPEUTICS HLDG's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for MODUS THERAPEUTICS HLDG (None–None)
The table below shows the annual net assets of MODUS THERAPEUTICS HLDG from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to MODUS THERAPEUTICS HLDG's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
MODUS THERAPEUTICS HLDG Competitors by Market Cap
The table below lists competitors of MODUS THERAPEUTICS HLDG ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Hoyne Bancorp, Inc. Common Stock
NASDAQ:HYNE
|
$137.70K |
|
BOEF39
SA:BOEF39
|
$137.71K |
|
Economic Investment Trust Ltd
TO:EVT
|
$137.78K |
|
Maj Invest - Globale Obligationer
CO:MAJGO
|
$137.86K |
|
IHI Corp
BE:IWJ
|
$137.43K |
|
CF Acquisition Corp. VII Warrant
NASDAQ:CFFSW
|
$137.42K |
|
TME Pharma N.V.
PA:ALTME
|
$137.38K |
|
Kuchai Develop Bhd
KLSE:2186
|
$137.38K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in MODUS THERAPEUTICS HLDG's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares MODUS THERAPEUTICS HLDG's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently MODUS THERAPEUTICS HLDG utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares MODUS THERAPEUTICS HLDG's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| MODUS THERAPEUTICS HLDG (99Z) | €- | N/A | N/A | $137.63K |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |